190P Combination of IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale. (December 2022) - Paturel, C.L.; Anceriz, N.; Eyles, J.; Lapointe, J-M.; Denis, C.; Breso, V.; Courtois, R.; Augier, S.; Brown, L.; Luheshi, N.; Watkins, A.; Cooper, Z.A.; et al.